Tvardi Therapeutics
TVRD
135 hedge funds and large institutions have $438M invested in Tvardi Therapeutics in 2019 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 35 increasing their positions, 43 reducing their positions, and 21 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more capital invested
Capital invested by funds: $315M → $438M (+$123M)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
5% more call options, than puts
Call options by funds: $16.3M | Put options by funds: $15.6M
1% more funds holding
Funds holding: 134 → 135 (+1)
0.14% less ownership
Funds ownership: 1.71% → 1.57% (-0.14%)
19% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$4.45M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.33M |
| 3 |
First Manhattan
New York
|
+$2.4M |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$2.02M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$7.62M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.94M |
| 3 |
Renaissance Technologies
New York
|
-$5.37M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.88M |
| 5 |
Millennium Management
New York
|
-$4.8M |
TVRD Hedge Fund Activity: Q1 2019 in Review
135 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2019, worth a combined $438M — up 39% from $315M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TVRD positions and 21 closed out — a net gain of 1 holder — while 35 added to existing stakes and 43 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $4.45M. The largest seller was ETF Managers Group, exiting entirely with an estimated $7.62M sold.
- 135 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2019, up from 134 in Q4 2018.
- Funds reported $438M of Tvardi Therapeutics stock for Q1 2019, up 39% quarter-over-quarter.
- 22 funds opened new Tvardi Therapeutics positions in Q1 2019 and 21 closed out, a net change of +1 holder.
- The largest Tvardi Therapeutics buyer in Q1 2019 was Citadel Advisors, an estimated $4.45M added.
- The largest Tvardi Therapeutics seller in Q1 2019 was ETF Managers Group, an estimated $7.62M sold.
Based on aggregated 13F filings for Q1 2019.